Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANASDAQ:CDIONASDAQ:NLSPNASDAQ:TENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$31.32$24.33M0.4123,653 shs237,144 shsCDIOCardio Diagnostics$0.21-46.7%$0.40$0.18▼$1.77$11.16M3.72.61 million shs8.62 million shsNLSPNLS Pharmaceutics$1.68-1.2%$1.51$1.30▼$18.39$6.05M-0.21846,708 shs30,329 shsTENXTenax Therapeutics$5.73+2.8%$5.91$2.77▼$7.89$23.75M1.92160,400 shs12,250 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%+9.69%+6.40%-39.53%CDIOCardio Diagnostics-46.23%-46.50%-32.34%-61.68%-70.86%NLSPNLS Pharmaceutics-1.17%+10.89%+23.53%-10.16%+1,112.12%TENXTenax Therapeutics+2.78%-0.09%-3.78%-20.82%+59.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.4179 of 5 stars3.05.00.04.20.60.80.0CDIOCardio Diagnostics1.7861 of 5 stars3.53.00.00.01.11.70.0NLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/AN/AN/ATENXTenax Therapeutics1.6205 of 5 stars3.63.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 2.00Hold$83.52∞ UpsideCDIOCardio Diagnostics 3.00Buy$2.00834.58% UpsideNLSPNLS Pharmaceutics 0.00N/AN/AN/ATENXTenax Therapeutics 3.25Buy$18.00214.41% UpsideCurrent Analyst Ratings BreakdownLatest NLSP, CDIO, CARA, and TENX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/10/2025TENXTenax TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$20.003/10/2025TENXTenax TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00CDIOCardio Diagnostics$34.89K319.83N/AN/A$0.14 per share1.53NLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/A$27.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%5/12/2025 (Estimated)CDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-22,732.03%-258.85%-191.20%5/21/2025 (Estimated)NLSPNLS Pharmaceutics-$12.17MN/A0.00∞N/AN/AN/AN/A5/21/2025 (Estimated)TENXTenax Therapeutics-$7.71M-$5.32N/AN/AN/AN/A-46.00%-42.65%5/13/2025 (Estimated)Latest NLSP, CDIO, CARA, and TENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025N/ACDIOCardio Diagnostics-$0.06N/AN/AN/A$0.05 millionN/A5/13/2025Q1 2025TENXTenax Therapeutics-$0.48N/AN/AN/AN/AN/A3/25/2025Q4 2024TENXTenax Therapeutics-$0.52-$0.18+$0.34-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71CDIOCardio DiagnosticsN/A8.508.50NLSPNLS PharmaceuticsN/A0.15N/ATENXTenax TherapeuticsN/A38.9538.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%CDIOCardio Diagnostics8.06%NLSPNLS PharmaceuticsN/ATENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%CDIOCardio Diagnostics22.30%NLSPNLS Pharmaceutics16.40%TENXTenax Therapeutics3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableCDIOCardio Diagnostics152.15 million40.52 millionNot OptionableNLSPNLS Pharmaceutics63.60 million3.01 millionNot OptionableTENXTenax Therapeutics94.15 million3.28 millionNot OptionableNLSP, CDIO, CARA, and TENX HeadlinesRecent News About These CompaniesTenax Therapeutics (NASDAQ:TENX) Coverage Initiated at StockNews.comMay 8 at 2:07 AM | americanbankingnews.comTenax Therapeutics (NASDAQ:TENX) Research Coverage Started at StockNews.comMay 3, 2025 | americanbankingnews.comTenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsApril 16, 2025 | seekingalpha.comTenax Therapeutics files to sell 4.14M shares of common stock for holdersApril 16, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTenax Therapeutics reports Q4 EPS (18c), consensus (43c)March 27, 2025 | markets.businessinsider.comTenax Therapeutics (TENX) Gets a Buy from William BlairMarch 27, 2025 | markets.businessinsider.comTenax Therapeutics: Q4 Earnings SnapshotMarch 25, 2025 | timesunion.comTenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | globenewswire.comTenax Therapeutics Inc TENXMarch 15, 2025 | morningstar.comRoth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)March 6, 2025 | markets.businessinsider.comTenax Therapeutics expands Phase 3 LEVEL program for TNX-103March 5, 2025 | markets.businessinsider.comTenax Therapeutics prices 378,346 shares at $6.04 in private placementMarch 5, 2025 | markets.businessinsider.comTenax Therapeutics Announces $25 Million Private PlacementMarch 5, 2025 | globenewswire.comTenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEFMarch 5, 2025 | globenewswire.comTenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare ConferenceMarch 3, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 31, 2025 | globenewswire.comTenax Therapeutics, Inc. Common Stock (TENX) Insider ActivityJanuary 28, 2025 | nasdaq.comTenax Therapeutics Appoints Gillian Andor Vice President, Clinical OperationsJanuary 22, 2025 | markets.businessinsider.com(TENX) Pivots Trading Plans and Risk ControlsJanuary 1, 2025 | news.stocktradersdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNLSP, CDIO, CARA, and TENX Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Cardio Diagnostics NASDAQ:CDIO$0.21 -0.19 (-46.67%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$0.22 +0.01 (+3.27%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.NLS Pharmaceutics NASDAQ:NLSP$1.68 -0.02 (-1.17%) Closing price 05/8/2025 03:52 PM EasternExtended Trading$1.65 -0.03 (-1.79%) As of 05/8/2025 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Tenax Therapeutics NASDAQ:TENX$5.72 +0.16 (+2.78%) Closing price 05/8/2025 03:58 PM EasternExtended Trading$5.82 +0.10 (+1.66%) As of 05/8/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
